TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02772341

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Salt room with halogenerator
Description: Patients were assigned to 14 sessions (7 weeks, twice weekly, 45 minutes each treatment) sitting in a salt room with salt aerosol produced by a halogenerator (study group) or halotherapy without salt aerosol (placebo). Both the walls and the ceiling of the salt room are completely covered with ESCO-(European Salt Company) type certified-origin rock salt. The temperature (20-24°C) and humidity (44-60%) are at constant values. The halogenerator is located outside the salt room.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Salt room without halogenerator
Description: Patients were assigned to 14 sessions (7 weeks, twice weekly, 45 minutes each treatment) sitting in a salt room without salt aerosol (placebo). Both the walls and the ceiling of the salt room are completely covered with ESCO-(European Salt Company) type certified-origin rock salt. The temperature (20-24°C) and humidity (44-60%) are at constant values.
Study: NCT02244385

Intervention type: OTHER
Intervention: no intervention
Study: NCT03181828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetohydroxamic Acid Oral Tablet
Description: A single oral dose of 60 mg/kg acetohydroxamic acid rounded to the nearest 250 mg tablet.
Study: NCT02865616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MET-2
Description: Microbial Ecosystem Therapeutics (MET) is a new treatment approach for debilitating recurrent Clostridium difficile infection that has been developed as an alternative to fecal transplantation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Patients will be on vancomycin to control symptoms up until the time of the treatment. Patient must hold their p.o. vancomycin for 24 hours prior to receiving the first dose.
Study: NCT02945501

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroConn DC Stimulator PLUS
Description: Prior to bedtime on the sleep restriction night, 4 transcranial stimulation electrodes (two on each hemisphere) will be applied to the scalps of each subject. Subjects will receive a one hour period of SO stimulation, for a total of approximately two hours of sleep.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM TES
Description: Prior to bedtime on the sleep restriction night, 4 placebo transcranial stimulation electrodes (two on each hemisphere) will be applied to the scalps of each subject. Subjects will sleep for approximately 2 hours without stimulation.
Study: NCT02119858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green solution
Description: Given transperineally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diffuse optical imaging
Description: Undergo near infrared fluorescence imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robot-assisted laparoscopic surgery
Description: Undergo robot-assisted laparoscopic radical prostatectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic lymphadenectomy
Description: Undergo lymphadenectomy
Study: NCT03341559

Intervention type: DEVICE
Intervention: Spatial Frequency Domain Imaging (SFDI)
Description: Observational study to measure perfusion in lower extremities for prediction of both healing and formation of diabetic foot ulcers using Reflect RS

Intervention type: DEVICE
Intervention: Spatial Frequency Domain Imaging (SFDI)
Description: Observational study to measure perfusion in lower extremities for prediction of both healing and formation of diabetic foot ulcers using Reflect RS
Study: NCT03181828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetohydroxamic Acid Oral Tablet
Description: A single oral dose of 60 mg/kg acetohydroxamic acid rounded to the nearest 250 mg tablet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No treatment
Description: No treatment
Study: NCT04434612

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OXSIGHT smart glasses
Description: OXSIGHT smart glasses are head-mounted electronic LVAs designed for LV patients with visual field loss.
Study: NCT00958659

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00401414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: 2 mg tablets take as directed by study staff (based on INR)
Study: NCT00632866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine : 200mg / day since 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo : 2cp/ day since 24 weeks
Study: NCT04438980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: -A dose of 120 mg/day of methylprednisolone for 3 days, administered by intravenous infusión

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: -An infusion bag of 100 mL of 0.9% saline
Study: NCT03181828

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No treatment
Description: No treatment
Study: NCT03052751

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered in period 1 of dosage regimen 2.
Study: NCT02199964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin 0.05% emulsion
Description: Topical therapy for dry eye

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endura, Refresh artificial tears
Description: Over the counter therapy for dry eye, used 4 times a day
Study: NCT01380561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asimadoline
Description: 10mg \[14\]C labelled asimadoline Day 1 then 7 doses 0.5 mg asimadoline bid beginning on Day 2 and ending on Day 5.
Study: NCT03099109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3321367
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3321367
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3321367
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3321367
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3321367
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3321367
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3300054
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3300054
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3300054
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3300054
Description: Administered IV
Study: NCT02490631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate cloths
Description: Cleansing twice pre-operatively jawline to toes with 2% chlorhexidine gluconate cloths
Study: NCT02877225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib (test treatment) 140 milligram (mg), tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib (test treatment) 140 milligram (mg), tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMBRUVICA
Description: IMBRUVICA (reference treatment), 140-mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMBRUVICA
Description: IMBRUVICA (reference treatment), 140-mg capsule
Study: NCT05475314

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ReFerm(R)
Description: Enemas of approx 250 mL twice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: ReFerm(R)
Description: Enemas of approx 250 mL twice daily
Study: NCT04186312

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: ACCESS - Accessing Campus Connections & Empowering Student Success
Description: Cognitive-Behavioral Treatment delivered across 2 semesters via group and individual mentoring sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACCESS - Accessing Campus Connections & Empowering Student Success
Description: Cognitive-Behavioral Treatment delivered across 2 semesters via group and individual mentoring sessions
Study: NCT00972374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 ug Brimonidine Implant
Description: 400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.
Study: NCT03656718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHuPH20
Description: Specified dose on specified days Permeation enhancer

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: (IV) Specified Dose on Specified Days
Study: NCT00972374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 ug Brimonidine Implant
Description: 200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham (no implant)
Description: Sham Posterior Segment Drug Delivery system on Day 1 in the study eye.
Study: NCT01800747

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antibiotic prescription strategies
Description: The patients enrolled will be randomized between three treatment strategies or arms. Patients randomized to delayed treatment arm or direct treatment, doctors can choose the antibiotic that they consider appropriate depending on such local resistance or practice.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic prescription strategies
Description: The patients enrolled will be randomized between three treatment strategies or arms. Patients randomized to delayed treatment arm or direct treatment, doctors can choose the antibiotic that they consider appropriate depending on such local resistance or practice.
Study: NCT02943837

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Device: 22G FNA needle

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Device: 20G FNB needle
Study: NCT01454726

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diaoshi Jifa therapy plus the Western medical treatment.
Description: Diaoshi Jifa treatment
Study: NCT02460809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: Transcranial direct current stimulation (tDCS) uses two surface electrodes placed on the scalp. These electrodes pass a low voltage current and modulate membrane potentials of underlying neurons.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: Transcranial direct current stimulation (tDCS) uses two surface electrodes placed on the scalp. These electrodes pass a low voltage current and modulate membrane potentials of underlying neurons.
Study: NCT00669708

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cooling compound (ph5 Eucerin)
Description: application twice daily to the skin

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: cooling compound (ph5 Eucerin)
Description: application twice daily to the skin
Study: NCT03353480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Tablet manufactured in China
Description: 250 mg Azithromycin Tablet manufactured in China
Study: NCT03656718

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: (IV) Specified Dose on Specified Days
Study: NCT03353480

Intervention type: DRUG
Group type: OTHER
Intervention: Azithromycin Tablet manufactured in US
Description: 250 mg Azithromycin Tablet manufactured in US
Study: NCT03363516

Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebral 3 Tesla MRI
Description: Subjects will be examined using a 3 Tesla MR750 GE MRI scanner with an eight-channel head coil. All participants will undergo the same MRI protocol, including: whole-brain 3D T1-weighted spoiled gradient recalled (SPGR) (BRAVO, voxel size of 1 × 1 × 1 mm3), DTI (voxel size 2 × 2 × 2 mm3, 27 directions with gradients at a b-value of 1,000 s/mm2 and 4 b = 0 images) and conventional 2D T2-weighted,T2 (FLAIR) and T2 gradient echo.
Study: NCT01412294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine, Cisplatin
Description: Drug: Capecitabine Capecitabine will be administered at 1,000 mg/m2 orally, twice daily (2,000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.~Drug: Cisplatin Cisplatin will be administered at 80 mg/m2 by intravenous infusion on Day 1 of each 21-day treatment cycle.
Study: NCT02800317

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RISAS
Description: RISAS procedure contains Radioactive Iodine Seed localisation in the Axilla in axillary node positive breast cancer combined with a Sentinel node procedure.
Study: NCT01473602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Administered by SC injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by SC injection

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium supplementation
Description: Administered orally

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Description: Administered orally

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D supplementation
Description: Administered orally

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Description: Administered orally
Study: NCT02857062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: E45 Eczema Repair Emollient
Description: E45 Eczema Repair Emollient
Study: NCT02824042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anetumab ravtansine (BAY94-9343)
Description: Anetumab ravtansine given IV On Day 1 of each 21-day treatment cycle Part 1: Cycle 1 Day 1: 6.5 mg/kg of body weight (BW) Cycle 2 Day 1: 0.6 mg/kg BW Part 2: Cycle 1 Day 1: 6.5 mg/kg BW Cycle 2 Day 1: 6.5 mg/kg BW (planned dose) Continuous treatment: Cycles ≥3 Day 1: 6.5 mg/kg BW once every 3 weeks (Q3W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole 100 mg oral capsules given by mouth Cycle 1 (Day 18): 200 mg twice daily (BID) (Days 19 - 21): 200 mg once daily (QD) Cycle 2 (Days 1-8): 200 mg QD 12 days in total (Part 1 or Part 2)
Study: NCT03814824

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: IRIS (Intelligent real-time image segmentation)
Description: IRIS has the ability to identify and display three specific images features that may correlate with dysplasia that are represented in different color schemes.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: IRIS (Intelligent real-time image segmentation)
Description: IRIS has the ability to identify and display three specific images features that may correlate with dysplasia that are represented in different color schemes.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: VLE (Volumetric laser endomicroscopy)
Description: VLE uses infrared light to produce real time high-resolution cross sectional imaging of the esophagus.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: VLE (Volumetric laser endomicroscopy)
Description: VLE uses infrared light to produce real time high-resolution cross sectional imaging of the esophagus.
Study: NCT06199856

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound scan
Description: ultrasound scan

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound scan
Description: ultrasound scan
Study: NCT02582593

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MedX 1116 Rehab Console
Description: This intervention makes use of transcranially applied near infrared light using light emitting diodes. Near infrared light will be applied to the scalp for a period of 1 hour at each session. A total of six session will be held.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MedX 1116 Rehab Console
Description: This intervention makes use of transcranially applied near infrared light using light emitting diodes. Near infrared light will be applied to the scalp for a period of 1 hour at each session. A total of six session will be held.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MedX 1116 Rehab Console
Description: This intervention makes use of transcranially applied near infrared light using light emitting diodes. Near infrared light will be applied to the scalp for a period of 1 hour at each session. A total of six session will be held.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham MedX 1116 Rehab Console
Description: This intervention makes use of sham transcranially applied near infrared light using light emitting diodes. Light emitting diodes (but not near-infrared light) will be applied to the scalp for a period of 1 hour at each session. A total of six session will be held.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham MedX 1116 Rehab Console
Description: This intervention makes use of sham transcranially applied near infrared light using light emitting diodes. Light emitting diodes (but not near-infrared light) will be applied to the scalp for a period of 1 hour at each session. A total of six session will be held.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham MedX 1116 Rehab Console
Description: This intervention makes use of sham transcranially applied near infrared light using light emitting diodes. Light emitting diodes (but not near-infrared light) will be applied to the scalp for a period of 1 hour at each session. A total of six session will be held.
Study: NCT01317199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Muscadine Plus Grape Skin Extract
Description: Phase I: Dose escalation starts at 500mg pills given by mouth once daily for 28 days per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose MPX
Description: Randomly-assigned participants receive one capsule of drug (500mg MPX) and seven capsules of placebo composed of pulverized rice, once daily for up to 12 cycles (28 days per cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose MPX
Description: Randomly-assigned participants receive 8 capsules of drug (4000mg MPX) once daily for up to 12 cycles (28 days per cycle).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Randomly-assigned participants receive 8 capsules once daily of placebo composed of pulverized rice for up to 12 cycles (28 days per cycle).
Study: NCT02563574

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: A type of counseling aimed at reducing consumption of alcohol.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire assessment
Description: Several different types of questionnaires will be fill out by the participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire assessment
Description: Several different types of questionnaires will be fill out by the participants.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neurocognitive assessments
Description: Several different types of neurocognitive assessment will be performed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurocognitive assessments
Description: Several different types of neurocognitive assessment will be performed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood specimens
Description: Blood specimens will be used to measure the immunological, virologic, and hepatic status, as well as other biomarkers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood specimens
Description: Blood specimens will be used to measure the immunological, virologic, and hepatic status, as well as other biomarkers.
Study: NCT02070952

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CyberKnife Stereotactic Ablative Body Radiation Therapy
Description: The prescribed planned tumor volume (PTV) dose of 36.25 Gy shall be given in 5 fractions using CyberKnife Hypofractionated Stereotactic Ablative Body Radiation Therapy. PTV will be defined per parameters outlined in the protocol and will at minimum include the entire prostate gland.
Study: NCT02209220

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positive airway pressure for the treatment of OSA

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positive airway pressure for the treatment of OSA
Study: NCT03273088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: A single dose of etanercept (25mg/0.5ml prefilled syringe) was administered subcutaneously to healthy subjects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: A single dose of etanercept (25mg/0.5ml prefilled syringe) was administered subcutaneously to healthy subjects.
Study: NCT00735748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol per os (Tradonal Odis® orodispersible tablets)
Description: Administration of 1 unit dose of 50 mg tramadol perorally given in 3 unit dosages

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol IV (Tradonal® IV)
Description: Administration of tramadol IV given in 3 unit dosage of 35 mg
Study: NCT03128801

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Global Stretching Program
Description: Participants will be submitted to a GSP in self-management postures weekly for 40 minutes session conducted by one one physical therapist, certified to use the technique (Stretching Global Active). The GSP will last for a period of 8 weeks. The protocol is based on the study of Lawand et al (2015) who used all postures global therapeutic stretching. The investigators will use six self-management postures in a standardized manner, each of which will last for 10 to 20 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stabilization Exercises
Description: The exercise protocol and criteria to increase exercise progression was previously described by Hicks et al (2005). It will be directed by a single therapist one to one session based on specific criteria (being able to maintain muscle contraction eight seconds during 30 repetitions in bilateral exercises or during 20 repetitions for unilateral exercises). Each session will be conducted weekly for 40 minutes.
Study: NCT03514823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training (IMT)
Description: Inspiratory muscle training (IMT) are breathing exercises used to increase strength and endurance of the respiratory muscles.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No Inspiratory Muscle Training (IMT)
Description: No inspiratory muscle training.
Study: NCT01374516

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live, attenuated, dengue serotype 1, 2, 3, 4 virus
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: (NaCl) 0.9% solution
Description: 0.5 mL, Subcutaneous